BIO Stock Analysis — Bio-Rad Laboratories
Sector: Healthcare
AI Verdict
Bio-Rad trades at 27.4x next year's earnings while analysts expect a -67.1% drop in EPS — that's paying a premium the numbers don't yet support, and the moat in lab workflows will be tested if earnings disappoint further.
Competitive Moat
Bio-Rad supplies essential life science research and clinical diagnostics tools, with a defensible moat in proprietary reagents and instrumentation that are deeply embedded in academic and clinical workflows. Its installed base and recurring consumables revenue create switching costs for labs standardized on Bio-Rad systems.
Summary
Forward P/E has jumped to 27.4x as the market braces for a steep -67.1% drop in earnings, making the stock's valuation a key debate.
Where It Stands
Bio-Rad delivered just 1.9% revenue growth last year, and at 27.4x forward earnings, it trades at a steep premium to the 22x healthcare median despite consensus expecting EPS to fall by -67.1%.
Key Metrics
- Trailing P/E: 9.0x
- Forward P/E: 27.4x
- Earnings Growth: -0.7%
- Revenue Growth: +0.0%
- 52-Week High: $343.12
- 52-Week Low: $211.43
Analyst Consensus
5 Buy · 5 Hold · 0 Sell (10 analysts)
Bull Case
The trailing P/E of 9.0x suggests the market is looking past a near-term earnings collapse to a potential recovery, betting on the stickiness of Bio-Rad's installed base.
Bear Case
If the forward P/E of 27.4x compresses to the sector median of 22x on weak EPS, the stock could lose another 20% from here.
Catalyst to Watch
Watch upcoming earnings reports for any sign that the -67.1% EPS decline is less severe than feared, which could justify the premium multiple.